No Data
No Data
Johnson & Johnson (JNJ.US) is negotiating to acquire the $10 billion market cap biotech star Intra-Cellular, and the medical merger wave is surging again!
Johnson & Johnson is in talks to acquire the biopharmaceutical company Intra-Cellular Therapies Inc., which focuses on treating central nervous system diseases, and both parties may reach an agreement as early as this week.
J&J Explores Takeover Bid for Intra-Cellular Therapies, Bloomberg Reports
Express News | Johnson & Johnson Is Exploring Bid for Intra-Cellular Therapies - Bloomberg News
Express News | Johnson & Johnson will seek to bid for the biopharmaceutical company Intra-Cellular Therapies.
Walgreens Boots Alliance, Aurora Innovation And Delta Air Lines Are Among Top Large Cap Gainers Last Week (Jan 6-10): Are The Others In Your Portfolio?
BofA Securities Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Raises Target Price to $118